Revenue Sharing Agreement with Idorsia Pharmaceuticals Ltd

Actelion Pharmaceuticals Ltd, J&J and Idorsia Pharmaceuticals Ltd, have entered into the Revenue Sharing Agreement in respect of ponesimod and cadazolid. Under the terms of the Revenue Sharing Agreement, Idorsia Pharmaceuticals Ltd is entitled to receive quarterly payments of 8% of the aggregate net sales of ponesimod and cadazolid products from Actelion Pharmaceuticals Ltd. For each of ponesimod and cadazolid, payments will be made under the Revenue Sharing Agreement for fifteen years from the latest launch of a product containing ponesimod or cadazolid (as applicable) in (i) the United States, (ii) Canada or (iii) any one of the United Kingdom, France, Germany, Italy and Spain.

IDENTIFYING INNOVATIVE IDEAS TO TURN THEM INTO NEW BUSINESS OPPORTUNITIES

Actelion / Nippon Shinyaku alliance

Actelion and Nippon Shinyaku entered into an exclusive worldwide alliance in April 2008 to collaborate on selexipag, the only oral, selective IP receptor agonist targeting the prostacyclin pathway, for patients suffering from pulmonary arterial hypertension (PAH).

Selexipag was originally discovered and synthesized by Nippon Shinyaku and was first commercialized by Actelion in the US in January 2016. Since then Uptravi have been launched in many other countries around the world.

Actelion is responsible for global development and commercialization of selexipag outside Japan, while the two companies will co-develop and co-commercialize the drug in Japan.

Actelion / Bayer AG alliance

Actelion holds the exclusive US rights for inhaled iloprost, marketed under the brand name Ventavis®, an inhaled treatment for pulmonary arterial hypertension (PAH), licensed from Bayer Schering Pharma AG (through the acquisition of CoTherix Inc.).

Actelion has the US development responsibilities, and has established a joint Development and Commercialization Committee for future collaboration with Bayer Schering Pharma AG. Actelion books all sales of Ventavis® in the US.

Actelion / Oxford GlycoSciences alliance

In November 2002, Actelion in-licensed miglustat, the active ingredient of Zavesca®, from Oxford GlycoSciences (UK) Ltd. Zavesca came to the market in the European Union in March 2003, followed by the United States in January 2004.

In November 2005, Actelion entered an agreement with UCB S.A., the legal successor to Oxford GlycoSciences under which UCB S.A. assigned all rights and obligations regarding miglustat, including worldwide marketing rights, to Actelion (except in Israel, the West Bank and the Gaza Strip).

"I enjoy working for a company with innovative products and innovative people."

Key Account Manager, Sales and Marketing, Germany